Mara Aspinall is a healthcare industry leader who successfully engineers bold moves that strengthen businesses and advance the life sciences community.
She is a founder of Dx Insights, an organization dedicated to educating healthcare stakeholders on the power and impact of diagnostics to improve the care of patients and to reduce the cost of treatment. DxInsights gathers the most relevant information on the industry and communicates that through educational White Papers, a central reference website and national summit meepinall is a healthcare industry leader who successfully engineers bold moves that strengthen businesses and advance the life sciences community.
Aspinall is the former President and CEO of Ventana Medical Systems. Ventana, a member of the Roche Group, is a worldwide leader in the development, manufacturing and commercialization of tissue-based cancer diagnostic products that enable the delivery of personalized healthcare to patients. During her tenure, Ventana substantially grew revenue, profit and market share and was established as the world’s leading oncology companion diagnostics developer and manufacturer. She is currently the CEO of Health Catalysts, a consulting firm dedicated to increasing growth and impact of early stage life science companies.
Previously, Aspinall spent 12 years with Genzyme Corporation where she held leadership roles including President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was also the Founder, CEO and Director of On-Q-ity, a research based company focused on transforming cancer patient management through the capture of circulating tumor cells (CTCs) in a patient’s blood.
A dynamic participant in the life sciences community, Aspinall has spearheaded many initiatives to educate policymakers about diagnostics, genomics, and personalized medicine. Most recently, she has founded the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the first school dedicated entirely to Diagnostics as an independent discipline. In addition, she founded DxInsights, an institute committed to expanding knowledge on the importance of diagnostics in improving patient care. She is also a founder of the European Personalized Medicine Association (EPEMED) and a former Director of the US Personalized Medicine Coalition (PMC).
Aspinall is a Director of Safeguard Scientific (NYSE:SFE) a creative public company providing growth capital for entrepreneurial and innovative healthcare and technology companies. Mara spent 15 years on the Board of the Dana Farber Cancer Institute, chairing the Science Committee and three years as Board member of Blue Cross Blue Shield Massachusetts. She was an active member of the Secretary of Health and Human Services’ Advisory Council on Genetics in the Obama and Bush Administrations.
Aspinall chairs the Arizona Biosciences Board, a group led by CEOs in multiple industries dedicated to improving the state’s atmosphere for technology companies. She is also a Board member of Science Foundation Arizona, the Southern Arizona Leadership Council and the Tucson Regional Economic Opportunities organization.
Aspinall has written several articles, case studies and editorials on healthcare topics. In 2010 she was named one of the “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine.
Aspinall started her business career at Bain & Company, an international strategic consulting firm. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.